El-Mowafy Mohammed, Elgaml Abdelaziz, El-Mesery Mohamed, Sultan Salma, Ahmed Tamer A E, Gomaa Ahmed I, Aly Mahmoud, Mottawea Walid
Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Department of Microbiology and Immunology, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt.
Biology (Basel). 2021 Jan 13;10(1):55. doi: 10.3390/biology10010055.
The gut-liver-axis is a bidirectional coordination between the gut, including microbial residents, the gut microbiota, from one side and the liver on the other side. Any disturbance in this crosstalk may lead to a disease status that impacts the functionality of both the gut and the liver. A major cause of liver disorders is hepatitis C virus (HCV) infection that has been illustrated to be associated with gut microbiota dysbiosis at different stages of the disease progression. This dysbiosis may start a cycle of inflammation and metabolic disturbance that impacts the gut and liver health and contributes to the disease progression. This review discusses the latest literature addressing this interplay between the gut microbiota and the liver in HCV infection from both directions. Additionally, we highlight the contribution of gut microbiota to the metabolism of antivirals used in HCV treatment regimens and the impact of these medications on the microbiota composition. This review shed light on the potential of the gut microbiota manipulation as an alternative therapeutic approach to control the liver complications post HCV infection.
肠-肝轴是肠道(包括微生物群落,即肠道微生物群)与肝脏之间的双向协调关系。这种相互作用中的任何干扰都可能导致疾病状态,影响肠道和肝脏的功能。肝脏疾病的一个主要原因是丙型肝炎病毒(HCV)感染,已证明在疾病进展的不同阶段,HCV感染与肠道微生物群失调有关。这种失调可能引发炎症和代谢紊乱的循环,影响肠道和肝脏健康,并促进疾病进展。本综述讨论了从两个方向探讨HCV感染中肠道微生物群与肝脏之间这种相互作用的最新文献。此外,我们强调了肠道微生物群对HCV治疗方案中使用的抗病毒药物代谢的贡献以及这些药物对微生物群组成的影响。本综述阐明了操纵肠道微生物群作为控制HCV感染后肝脏并发症的替代治疗方法的潜力。